A Short History of Diagnostic Tests for von Willebrand Disease: In Memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988)

Jerry Koutts

doi:10.1055/s-2006-947858

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2006; 32(5): 445-455
DOI: 10.1055/s-2006-947858

A Short History of Diagnostic Tests for von Willebrand Disease: In Memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988)

Jerry Koutts¹

¹Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Australia

Abstract

ABSTRACT

By the end of the 1960s, von Willebrand disease (vWD) was accepted as a combined deficiency of factor (F) VIII coagulation and a plasma factor responsible for normal platelet adhesion. Just how these two functions related to each other was unclear, and the diagnostic tests available at the time were poorly reproducible, cumbersome, and unreliable. As a consequence, the condition was poorly delineated from other coagulation and platelet disorders. In the early 1970s, ristocetin-induced platelet aggregation was described and formed the basis of the first consistent and reliable test that quantified the platelet adhesive function missing in vWD. Immunoprecipitating techniques specific for the molecule missing in vWD were defined. The application of these technologies allowed a clearer understanding of the heterogeneity of vWD and continues to form a basis for the diagnosis of this condition. Concurrently, exploration of the structure and function of von Willebrand factor (vWF) has contributed greatly to the understanding of platelet physiology, ligand receptor interaction, and pathways of cellular interaction and activation. Despite all of the progress during the last 35 years, including extensive developments in the field of molecular biology and genetics of vWD, the diagnosis of this condition in many, if not most cases, remains controversial. The final plasma level of vWF is influenced substantially by epigenetic and environmental factors. This natural heterogeneity is further compounded by significant imprecision of existing tests. As a consequence, defining vWD on the basis of a variation from the normal range alone is more than likely to be incorrect. The high frequency of a positive bleeding disorder in the normal population does not assist discrimination. It has been suggested that the diagnosis of mild type 1 vWD be discarded because it does not exhibit consistent linkage to the VWF gene and does not predict bleeding.

KEYWORDS

von Willebrand disease (vWD) - diagnosis - history

Volltext

Referenzen

REFERENCES

1 von Willebrand A E. Hereditar pseudohemofili. Finska Laekaresaellsk Handl. 1926; 67 87-112
2 Duke W W. The pathogenesis of purpura hemorrhagica with special reference to the part played by blood platelets. Arch Intern Med. 1912; 10 445-469
3 Ivy A C, Nelson D, Bucher G. The standardization of certain factors in the cutaneous “venostasis bleeding time technique”. J Lab Clin Med. 1941; 26 1812-1822
4 Borchgrevink C F. The haemostatic effect of normal platelets in haemophilia and factor V deficiency. Acta Med Scand. 1961; 170 378-383
5 Salzman E W. Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Med. 1963; 62 724-735
6 Bowie E JM, Owen Jr C A, Thompson Jr J H et al.. Platelet adhesiveness in von Willebrand's disease. Am J Clin Pathol. 1969; 52 69-77
7 Larrieu M J, Caen J P, Meyer D O et al.. Congenital bleeding disorders with long bleeding time and normal platelet count. II. Von Willebrand's disease (report of thirty seven patients). Am J Med. 1968; 45 354-372
8 Rodgers R PC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990; 16 1-20
9 Lind S E. The bleeding time does not predict surgical bleeding. Blood. 1991; 77 2547-2552
10 Howard M A, Firkin B G. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971; 26 362-369
11 Howard M A, Sawers R J, Firkin B G. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood. 1973; 41 687-690
12 Weiss H J, Hoyer L W, Rickles F R et al.. Quantitative assay of a plasma factor, deficient in von Willebrand's disease, that is necessary for platelet aggregation. Relationship to factor VIII pro-coagulant activity and antigen content. J Clin Invest. 1973; 52 2708-2716
13 Jenkins C S, Meyer D, Dreyfus M D et al.. Von Willebrand factor and ristocetin. 1. Mechanism of ristocetin induced platelet aggregation. Br J Haematol. 1974; 28 561-578
14 Olson J D, Brockway W I, Fass D N. Evaluation of ristocetin-Willebrand factor assay and ristocetin induced platelet aggregation. Am J Clin Pathol. 1975; 63 210-218
15 Zimmerman T S, Ratnoff O D, Powell A E. Immunological differentiation of classical hemophilia (factor VIII deficiency) and von Willebrand's disease with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and an acquired anticoagulant against antihemophilic factor. J Clin Invest. 1971; 50 244-254
16 Zimmerman T S, Hoyer L W, Dickinson L, Edgington T S. Determination of the von Willebrand's disease antigen (factor VIII related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med. 1975; 86 152-159
17 Peake I R, Bloom A L. The use of an immunoradiometric assay for FVIII related antigen in the study of atypical von Willebrand's disease. Thromb Res. 1977; 10 27-32
18 Sixma J J, Wester J. The hemostatic plug. Semin Hematol. 1977; 14 265-299
19 Koutts J, Howard M A, Firkin B G. Factor VIII physiology and pathology in man. In: Brown E Progress in Hematology. XI. New York; Grune and Stratton 1979: 115-145
20 Zimmerman T S. Factor VIII/von Willebrand factor. Structure and function. Ann NY Acad Sci. 1987; 509 53-59
21 Vehar G A, Keyt B, Eaton D et al.. Structure of human factor VIII. Nature. 1984; 312 337-342
22 Ruggeri Z M, Zimmerman T S. Variant von Willebrand disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest. 1980; 65 1318-1325
23 Siedlecki C A, Lestini J, Kottke-Marchant K K et al.. Shear dependent changes in the three dimensional structure of human von Willebrand factor. Blood. 1996; 88 2939-2950
24 Ruggeri Z M. Von Willebrand factor. J Clin Invest. 1997; 99 559-564
25 Ginsburg D, Handin R I, Bonthron D T. Human von Willebrand factor (VWF): isolation of complementary DNA (cDNA) clones and chromosomal localisation. Science. 1985; 228 1401-1406
26 Sadler J E, Shelton-Inloes B B, Sorace J M et al.. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA. 1985; 82 6394-6398
27 Von Willebrand factor mutation database .http://Available at: http://www.vwf.group.shef.ac.uk/ Accessed on October 7, 2005
28 Ruggeri Z M. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003; 1 1335-1342
29 Ozaki Y, Asazuma N, Suzuki I et al.. Platelet GP-IX-V dependent signalling. J Thromb Haemost. 2005; 3 1745-1751
30 Watson S P, Auger J M, McCarty O JT et al.. GPVI and integrin alphaIIbeta3 signaling in platelets. J Thromb Haemost. 2005; 3 1752-1762
31 Coller B S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997; 99 1467-1471
32 Ruggeri Z M. Old concepts and new developments in the study of platelet aggregation. J Clin Invest. 2000; 105 699-701
33 Nilsson I M. von Willebrand's disease from 1926-1983. Scand J Haematol. 1984; 33(suppl 40) 21-43
34 Minot G. A familial hemorrhagic condition associated with a prolongation of the bleeding time. Am J Med Sci. 1928; 175 301-306
35 Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol. 1955; 1 20-24
36 Hardisty R M, Macpherson J C. A one stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Death Haemorrh. 1962; 7 215-228
37 Alexander B, Goldstein R. Dual hemostatic defect in pseudohemophilia. J Clin Invest. 1953; 32 551 (abst)
38 Nilsson I M, Blombäck M, von Fränckel I. On an inherited autosomal haemorrhagic diathesis with antihaemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand. 1957; 159 35-37
39 Shulman J, Smith C H, Erlandson M et al.. Vascular hemophilia. A familial hemorrhagic disease in males and females characterized by combined antihemophilic globulin deficiency and vascular abnormalities. Pediatrics. 1956; 18 347-361
40 Blackburn E K, Macfie J M, Monaghan J H, Page A P. Antihaemorphilic factor deficiency: capillary defects of von Willebrand type, and idiopathic thrombocytopenia occurring in one family. J Clin Path. 1961; 14 540-542
41 Nilsson I M, Blombäck M, von Blombäck B. Willebrand's disease in Sweden. Its pathogenesis and treatment. Acta Med Scand. 1959; 164 263-278
42 Cornu P, Larrieu M J, Caen J et al.. Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII. Br J Haematol. 1963; 9 189-202
43 Miller C H, Graham J B, Goldin L R et al.. Genetics of classic von Willebrand's disease. 1. Phenotypic variations within families. Blood. 1979; 54 117-136
44 Abildgaard C F, Suzuki Z, Harrison J et al.. Serial studies in von Willebrand's disease: variability versus “variants”. Blood. 1980; 56 712-716
45 Born G VR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1982; 194 827-829
46 Grundy W E, Sinclair A C, Theriault R J et al.. Ristocetin, antimicrobial properties. Antibiotics Ann. 1956-7; 1 687-698
47 Gangarosa E J. Complications of ristocetin therapy. Lancet. 1958; 1 1179-1180
48 Herting R J, Lees B, Zimmerman A J et al.. Ristocetin-a statistical review of 333 cases. JAMA. 1959; 170 176-178
49 Clancy R L, Jenkins E, Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopaenic purpure. N Engl J Med. 1972; 286 622-626
50 Clancy R, Jenkins E, Firkin B. Platelet defects in infectious mononucleosis. BMJ. 1971; 4 646-648
51 Van der Weyden M B, Clancy R L, Howard M A et al.. Qualitative platelet defects with reduced life span in acute leukaemia. Aust N Z J Med. 1972; 4 339-345
52 Howard M A, Hutton R A, Hardisty R M. Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. Br Med J. 1973; 2 586-588
53 Sadler J E. for the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease. Thromb Haemost. 1994; 71 520-525
54 Italian Working Group . Spectrum of von Willebrand's disease. A study of 100 cases. Br J Haematol. 1977; 35 101-112
55 Ruggeri Z M, Pareti F I, Mannucci P M et al.. Heightened interaction between platelets and factorVIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980; 302 1047-1051
56 Ware J, Dent J A, Azuma H et al.. Identification of a point mutation in type IIb von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci USA. 1991; 88 2946-2950
57 Randi A M, Rabinowitz I, Mancuso D J et al.. Molecular basis of von Willebrand disease type IIB. J Clin Invest. 1991; 87 1220-1226
58 Cooney K A, Nichols W C, Bruck M E et al.. The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding sequence. J Clin Invest. 1991; 87 1227-1233
59 Takahashi H. Studies in the pathophysiology and treatment of von Willebrand's disease. IV. Mechanisms of increased ristocetin induced platelet aggregation in von Willebrand's disease. Thromb Res. 1980; 19 857-867
60 Miller J I, Castella A. Platelet type von Willebrand's disease: characterization of a new bleeding disorder. Blood. 1982; 60 790-794
61 Weiss H J, Meyer D, Rabinowitz R et al.. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factorVIII/von Willebrand factor and enhanced absorbtion of its high molecular weight multimers. N Engl J Med. 1982; 306 326-333
62 Miller C H, Cunningham D, Lyle V A et al.. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet type von Willebrand's disease. Proc Natl Acad Sci USA. 1991; 88 4761-4765
63 Russell S D, Roth G J. Pseudo-von Willebrand's disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive platelet receptor. Blood. 1993; 81 1787-1791
64 Phillips D R, Jennings L K, Edwards H H. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol. 1980; 86 77-86
65 Coller B S, Peerschke E I, Scudder L E et al.. Studies with a murine monoclonal antibody that abolishes ristocetin induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood. 1983; 61 99-110
66 Nurden A J, Caen J P. Specific roles for platelet surface glycoproteins in platelet function. Nature. 1975; 255 720-722
67 Clementson K J, McGregor J L, James E et al.. Characterization of the platelet membrane glycoprotein abnormalities in Bernard Soulier syndrome and comparison with normal with by surface labelling techniques and high resolution two dimensional gel electrophoresis. J Clin Invest. 1982; 70 304-311
68 Fujimura Y, Titani K, Holland L Z et al.. von Willebrand factor: a reduced and alkylated 52/48 kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem. 1986; 261 381-385
69 Read M S, Shermer R W, Brinkhous K. Venom coagglutin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci USA. 1978; 75 4514-4518
70 Kirby E P. The agglutination of human platelets by bovine factor VIII. J Lab Clin Med. 1982; 100 963-976
71 Moake J L, Turner N A, Stathopoulos N A et al.. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress induced platelet aggregation. J Clin Invest. 1986; 78 1456-1461
72 Ikeda Y, Handa M, Kawano K et al.. The role of von Willebrand factor and fibrinogen in platelet aggregation under shear stress. J Clin Invest. 1991; 87 1234-1240
73 Pasi K J, Collins P W, Keeling D M et al.. von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation. Haemophilia. 2004; 10 218-231
74 Favaloro E J, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology. 1997; 29 385-391
75 Favaloro E J, Smith J, Petinos P et al.. On behalf of the RCPA quality assurance program (QAP) in haematology-haemostasis scientific advisory panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost. 1999; 82 1276-1282
76 Budde U, Drewke E, Mainusch K et al.. Laboratory diagnosis of congenital von Willebrand's disease. Semin Thromb Hemost. 2002; 28 173-190
77 Van Hoorelbeke K, Cauwenberghs N, Vandercasteele G et al.. A reliable von Willebrand factor: ristocetin co-factor enzyme linked immunoabsorbent assay to differentiate between type 1 and type 2 von Willebrand's disease. Semin Thromb Hemost. 2002; 28 161-166
78 Murdock P J, Woodhams B J, Mathews K B et al.. Von Willebrand factor activity detected in a monoclonal antibody based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost. 1997; 78 1272-1277
79 Favaloro E J, Grispo L, Exner T et al.. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II von Willebrand's disease. Blood Coagul Fibrinolysis. 1991; 2 285-291
80 van Mourik J A, Mochtar I A. Purification of human antihaemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta. 1970; 221 677-679
81 Hoyer I W, Shainoff J R. Factor VIII related protein circulates in human plasma as high molecular weight multimers. Blood. 1980; 55 1056-1059
82 Counts R B, Paskell S L, Elgee S. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest. 1978; 62 702-709
83 Over J, Bouma B M, van Mourik J A et al.. Heterogeneity of human Factor VIII. I. Characterisation of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med. 1978; 91 32-46
84 Sixma J J, Over J, Bouma B N et al.. Predominance of normal low molecular weight forms of factor VIII in “variant” von Willebrand's disease. Thromb Res. 1978; 12 929-935
85 Gralnick H R, Williams S B, Morisato D K. Effect of multimeric structure of factor VIII/von Willebrand factor protein on binding to platelets. Blood. 1981; 58 387-397
86 Koutts J, Stott L, Sawers R J. Variant pattern of von Willebrand's disease. Thomb Research. 1974; 5 557-564
87 Ruggeri Z M, Zimmerman T S. Von Willebrand factor and von Willebrand disease. Blood. 1987; 70 895-904
88 Holmberg L, Nilsson I M. Genetic variants of von Willebrand's disease. BMJ. 1972; 3 317-320
89 Firkin B, Firkin F, Stott L. von Willebrand's disease type B: a newly defined bleeding diathesis. Aust NZ J Med. 1973; 3 225-229
90 Meyer D, Jenkins C SP, Dreyfus M D et al.. Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol. 1974; 28 579-599
91 Peake I R, Bloom A L, Giddings J C. Inherited variants of factor VIII related protein in von Willebrand's disease. N Engl J Med. 1974; 291 113-117
92 Peake I R, Liddel M B, Moodie P et al.. Severe type III von Willebrand's disease caused by deletions of exon42 of the von Willebrand factor gene: family studies that identify carriers of the condition and compound heterozygous individuals. Blood. 1990; 75 654-661
93 Schneppenheim R, Kreey S, Bergmann F et al.. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet. 1994; 94 640-652
94 Zhang Z P, Lindsedt M, Falk G et al.. Nonsense mutations of the von Willebrand gene in patients with von Willebrand disease type III and type I. Am J Hum Genet. 1992; 51 850-858
95 Mannucci P M, Meyer D, Ruggeri Z M et al.. Precipitating antibodies in von Willebrand's disease. Nature. 1976; 262 141-142
96 Sadler J E, Gralnick H R. Commentary: a new classification for von Willebrand's disease. Blood. 1994; 84 676-679
97 Howard M A, Salem H H, Thomas K B et al.. Variant von Willebrand's disease type B revisited. Blood. 1982; 60 1420-1428
98 Mannucci P M, Lombardi R, Castaman C et al.. Von Willebrand disease “Vicenza” with larger than normal (supra-normal) von Willebrand factor multimers. Blood. 1988; 71 65-70
99 Ciavarella G, Ciavarella N, Antoncecchi S et al.. High resolution analysis of von Willebrand factor multimeric composition defines a new variant of type 1 von Willebrand's disease with aberrant structure, but presence of all size multimers (type 1C). Blood. 1985; 66 1423-1429
100 Lyons S E, Bruck M E, Bowie E J et al.. Impaired intracellular transport produced by a subset of Type IIA von Willebrand disease mutations. J Biol Chem. 1992; 267 4424-4430
101 Dent J A, Berkowitz S D, Ware J et al.. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in Type IIA von Willebrand factor. Proc Natl Acad Sci USA. 1990; 87 6306-6310
102 Schneppenheim R, Brassard J, Kray S et al.. Defective dimerization of von Willebrand factor subunits due to a Cys-Arg mutation in Type IID von Willebrand disease. Proc Natl Acad Sci USA. 1996; 93 3581-3586
103 Ginsburg D, Wagner D D. In: Hoffmann R, Benz EJ, Shattil SJ, et al Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA; Churchill Livingstone 2005: 2111-2114
104 Weiss H J, Kochwa S. Molecular forms of antihemophilic globulins in plasma, cryoprecipitate and after thrombin activation. Br J Haematol. 1970; 18 89-100
105 Weiss H J, Hoyer L W. Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science. 1973; 182 1149-1151
106 Owen W G, Wagner R H. Antihemophilic factor separation of an active fragment following dissociation by salts and detergents. Thromb Diath Haemorrh. 1972; 27 502-515
107 Zimmerman T S, Edgington T S. Factor VIII coagulant activity and factor VIII like antigen: independent molecular entities. J Exp Med. 1973; 138 1015-1020
108 Koutts J, Gude N, Firkin B G. The dynamic interrelationship between factor VIII and von Willebrand factor. Thromb Res. 1976; 8 533-541
109 Koutts J, Lavergne J M, Meyer D. Immunological evidence that human factor VIII is composed of two moieties. Br J Haematol. 1977; 37 415-427
110 Foster P A, Fulcher C A, Marti T et al.. A major factor VIII binding domain resides within the amino terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987; 262 8443-8446
111 Weiss H J, Sussman I I, Hoyer L W. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest. 1977; 60 390-404
112 Nishino M, Girma J-P, Rothschild C et al.. New variant of von Willebrand's disease with defective binding to factor VIII. Blood. 1989; 74 1591-1599
113 Sadler J E. Von Willebrand disease type: a diagnosis in search of a disease. Blood. 2003; 101 2089-2093
114 Rodeghiero F. Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia. 2002; 8 292-300
115 Alperin J B. Estrogen and surgery in women with von Willebrand's disease. Am J Med. 1982; 73 367-371
116 Hoyer L W. The factor VIII complex: structure and function. Blood. 1981; 58 1-13
117 Gill J C, Endres-Brooks J, Bauer P J et al.. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987; 69 1691-1695
118 Mannucci P M, Lattuada A, Castaman G et al.. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. Blood. 1989; 74 2433-2436
119 Mohlke K L, Ginsbrg D. Von Willebrand disease and quantitative variation in von Willebrand factor. J Lab Clin Med. 1997; 130 252-261
120 Werner E J, Broxson E H, Tucker E L et al.. Prevalence of von Willebrand disease in children: a multicentre study. J Pediatr. 1993; 123 893-898
121 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987; 69 454-459
122 Castaman G, Eikenboom J CL, Bertina R M et al.. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999; 82 1065-1070
123 Sadler J E, Mannucci P M, Berntrop E et al.. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000; 84 160-174
124 Kouides P A. Females with von Willebrand's disease: 72 years as the silent majority. Haemophilia. 1998; 4 665-676
125 Kouides P A. Menorrhagia from a haematologist's point of view. Part 1: initial evaluation. Haemophilia. 2002; 8 330-338
126 Foster P A. The reproductive health of women with von Willebrand disease unresponsive to DDAVP-results of an international survey. Thromb Haemost. 1995; 74 784-790
127 Biron C, Mahieu B, Rochette P et al.. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med. 1999; 134 605-609
128 Coller B S, Schneiderham P I. In: Hoffman R, Benz EJ, Shattil SJ, et al Haematology: Basic Principles and Practice. 4th ed. Philadelphia, PA; Churchill Livingstone 2005: 1976-1982

Jerry KouttsM.D.

Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, 2145 Australia

eMail: koutts@icpmr.wsahs.nsw.gov.au